Preimplantation Genetic Testing Market Size, Share, Opportunities, And Trends By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Molecule Polymorphism), By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Application (Aneuploidy, Single Gene Disorders, X-linked Disorders, Others), By End-User (Maternity Clinics, Hospitals, Others), And By Geography - Forecasts From 2024 To 2029

The preimplantation genetic testing market is estimated to grow at a CAGR of 10.70% during the forecast period. It was valued at US$808.519 million in 2022 and is projected to reach US$1,647.489 million by 2029.

Preimplantation genetic diagnosis (PGD) is implemented before the IVF procedure. Women who have had many miscarriages and final pregnancies with chromosome abnormalities have PGD sent in IVF cycles.

Couples who are at chance of genetic disorders can asset from preimplantation genetic testing. The major variable impacting the preimplantation genetic treatment industry’s expansion is the developing frequency of infertility among people and rising hereditary issues.

Furthermore, preimplantation genetic testing is increasing in demand because it detects imperfect embryos and has some genetic disorders and other deficiencies that lead to the child being born with health abnormalities. People who have single-quality benefactors, sex-linked genetic disorders, chromosomal issues, or a history of numerous abortions are progressively utilizing preimplantation genetic testing strategies.

What are the preimplantation genetic testing market growth drivers?

• The growing prevalence of neo-natal deaths is projected to propel the market of preimplantation genetic testing expansion.

Many genetic deformities cause newborn deaths worldwide and hence will propel the preimplantation genetic treatment market growth. For instance, according to UNICEF, in 2022, the global mortality rate for neonatal deaths was estimated at 11 deaths per 1,000 children after the first month and before reaching age 1 and 9 deaths per 1,000 children after reaching age 1 and before age 5, resulting in approximately 6,300 neonatal deaths daily. Preimplantation genetic diagnosis helps in curbing this issue as it detects defective chromosomes at an early stage and prevents congenital genetic deformities in the fetuses. As the women’s age for childbearing increases, so does the use of preimplantation genetic testing.

• Rising adoption of polymerase chain reaction will bolster the preimplantation genetic testing market growth.

The polymerase chain reaction (PCR) is expected to hold the greatest share amid the estimated period owing to the major market penetration and rising cost-effectiveness with high accuracy of these tests are fueling the preimplantation genetic treatment industry. The PCR response raises the chance of detection of any chromosomal variations from the norm with a huge number of copies of a specific extent of the genome. This technological innovation is appropriate for the detection of all types of hereditary or genetic disorders.

• The growing prevalence of preimplantation genetic diagnosis and IVF prognosis is anticipated to boost the demand for preimplantation genetic testing.

The major variable driving the preimplantation genetic treatment market expansion is the increasing awareness among healthcare experts and customers about the genetic testing industry. The rising incidence of single gene disease and translocation cases led to the effective delivery of NGS technology for genetic testing. The preimplantation genetic diagnosis services help reduce the incidences of genetic diseases, which is done by embryo examination to determine specific gene mutations. The PGS services are also gaining popularity as they are suggested for couples with multiple IVF cycles, advanced age, and recurrent pregnancy loss.

A study presented at the National Society of Genetic Counselors' 41st Annual Conference in November 2022 reveals a significant increase in preimplantation genetic testing (PGT-M) as part of in vitro fertilization (IVF). The study found that the use of PGT-M increased by over 644% over a 17-year period, from 1% in 2004 to 7.44% of all IVF cycles in 2021, likely due to the rise in carrier screening and other genetic testing methods.

Besides, preimplantation genetic testing plays an imperative role in IVF prognosis because it is fundamental to examine the medical condition of the embryos, subsequently contributing to the development of IVF prognosis. The rise in demand for in vitro fertilization methods is increasing the request for preimplantation genetic testing methods. Additionally, many product launches by major market players are further fueling the preimplantation genetic treatment market growth. Rising infertility and increasing preference for IVF procedures are expected to drive the preimplantation genetic treatment market growth during the forecast period.

• Advancements in medical technologies and next-generation sequencing technology adoption are expected to propel the preimplantation genetic testing market’s expansion.

The growing demand for improved medical services and increasing income fuel opportunities for developing advanced diagnostic and treatment approaches. As the need to prevent physical abnormalities and health problems has increased, the preimplantation genetic treatment market has grown for early diagnostic approaches. These early diagnostic approaches are used during genetic invitro fertilization and other artificial insemination procedures. Preimplantation genetic testing strategies can detect inherited disorders, including inherent hearing loss, cystic fibrosis, and numerous more.

Next-generation sequencing (NGS) drives the preimplantation genetic treatment industry due to its accuracy, productivity, and comprehensive genetic data. The NGS strategy gives detailed hereditary examination, which results in progressed success rates of assisted reproductive methods. Besides, the adoption of florescent in-situ hybridization is additionally affecting the preimplantation genetic treatment industry due to the increasing need to detect chromosomal variations from the norm in embryos before implantation. Fish offers quick results and screens a constrained number of chromosomes at a time.

What are the key geographical trends shaping the preimplantation genetic testing market?

• Europe expects that the preimplantation genetic testing market will develop significantly.

The European region is anticipated to secure a sizable preimplantation genetic treatment market share. The industry will be fueled by the increasing prevalence of late pregnancies, the growing liberal screening regulations in various European countries, and the presence of leading market players.

Furthermore, Asia Pacific is anticipated to grow significantly during the forecast period due to advancements in reproductive health. High adoption of IVF and increasing consumer awareness are further fueling the preimplantation genetic treatment market growth.

Recent developments in the preimplantation genetic testing market:

• July 2023- Stanford Medicine researchers suggested that using in vitro fertilization with genetic testing for inherited diseases could significantly reduce costs for prospective parents carrying multiple diseases. Preimplantation genetic diagnostic testing during IVF (PGD-IVF) is also employed to screen for single-gene defects in nearly 400 other conditions.
• April 2023 -The HelpCureHD Foundation and Prelude Network launched the More Than Fertility campaign to increase awareness and educate about IVF with Preimplantation Genetic Testing.
• October 2022- Ovation Fertility partnered with Genomic Prediction to expand genetic testing options for parents. By licensing LifeView's PGT platform, Ovation offered comprehensive preimplantation genetic testing (PGT) for optimal-quality embryos for IVF transfer, enhancing the selection process for physicians and patients.

Preimplantation Genetic Testing Market Scope:

Report Metric	Details
Growth Rate	CAGR of 10.26% from 2022 to 2029
Study Period	2019 to 2029
Historical Data	2019 to 2022
Base Year	2023
Forecast Period	2024 – 2029
Forecast Unit (Value)	USD Billion
Segments Covered	Technology Procedure Type Application End-User Geography
Companies Covered	Milann Fertility Center Pac Genomics Thermo Fisher Scientific Natera Illumina
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Preimplantation Genetic Testing Market is analyzed into the following segments:

• By Technology
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Fluorescent In-Situ Hybridization
  • Comparative Genomic Hybridization
  • Single Molecule Polymorphism
• By Procedure Type
  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis
• By Application
  • Aneuploidy
  • Single Gene Disorders
  • X-linked Disorders
  • Others
• By End-User
  • Maternity Clinics
  • Hospitals
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. PREIMPLANTATION GENETIC TESTING MARKET BY TECHNOLOGY

5.1. Introduction

5.2. Next Generation Sequencing

5.3. Polymerase Chain Reaction

5.4. Fluorescent In-Situ Hybridization

5.5. Comparative Genomic Hybridization

5.6. Single Molecule Polymorphism

6. PREIMPLANTATION GENETIC TESTING MARKET BY PROCEDURE TYPE

6.1. Introduction

6.2. Preimplantation Genetic Screening

6.3. Preimplantation Genetic Diagnosis

7. PREIMPLANTATION GENETIC TESTING MARKET BY APPLICATION

7.1. Introduction

7.2. Aneuploidy

7.3. Single Gene Disorders

7.4. X-linked Disorders

7.5. Others

8. PREIMPLANTATION GENETIC TESTING MARKET BY END-USER

8.1. Introduction

8.2. Maternity Clinics

8.3. Hospitals

8.4. Others

9. PREIMPLANTATION GENETIC TESTING MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Technology

9.2.2. By Procedure Type

9.2.3. By Application

9.2.4. By End-User 

9.2.5. By Country

9.2.5.1. United States

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. South America

9.3.1. By Technology

9.3.2. By Procedure Type

9.3.3. By Application

9.3.4. By End-User 

9.3.5. By Country

9.3.5.1. Brazil

9.3.5.2. Argentina

9.3.5.3. Others

9.4. Europe

9.4.1. By Technology

9.4.2. By Procedure Type

9.4.3. By Application

9.4.4. By End-User 

9.4.5. By Country

9.4.5.1. United Kingdom

9.4.5.2. Germany

9.4.5.3. France

9.4.5.4. Spain

9.4.5.5. Others

9.5. Middle East and Africa

9.5.1. By Technology

9.5.2. By Procedure Type

9.5.3. By Application

9.5.4. By End-User 

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.2. UAE

9.5.5.3. Israel

9.5.5.4. Others

9.6. Asia Pacific

9.6.1. By Technology

9.6.2. By Procedure Type

9.6.3. By Application

9.6.4. By End-User 

9.6.5. By Country

9.6.5.1. Japan

9.6.5.2. China

9.6.5.3. India

9.6.5.4. South Korea

9.6.5.5. Indonesia

9.6.5.6. Thailand

9.6.5.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Milann Fertility Center

11.2. Pac Genomics

11.3. Thermo Fisher Scientific

11.4. Natera

11.5. Illumina

11.6. Johns Hopkins Medicine

11.7. NYU Langone Health

11.8. Cloudnine Fertility

11.9. MedGenome

11.10. CNY Fertility

Milann Fertility Center

Pac Genomics

Thermo Fisher Scientific

Natera

Illumina

Johns Hopkins Medicine

NYU Langone Health

Cloudnine Fertility

MedGenome

CNY Fertility